Protein C activation and factor Va inactivation on human umbilical vein endothelial cells

MF Hockin, M Kalafatis, M Shatos… - … thrombosis, and vascular …, 1997 - Am Heart Assoc
MF Hockin, M Kalafatis, M Shatos, KG Mann
Arteriosclerosis, thrombosis, and vascular biology, 1997Am Heart Assoc
The inactivation of factor Va was examined on primary cultures of human umbilical vein
endothelial cells (HUVECs), either after addition of activated protein C (APC) or after
addition of α-thrombin and protein C (PC) zymogen. Factor Va proteolysis was visualized by
Western blot analysis using a monoclonal antibody (αHVaHC No. 17) to the factor Va heavy
chain (HC), and cofactor activity was followed both in a clotting assay using factor V–
deficient plasma and by quantitation of prothrombinase function. APC generation was …
Abstract
The inactivation of factor Va was examined on primary cultures of human umbilical vein endothelial cells (HUVECs), either after addition of activated protein C (APC) or after addition of α-thrombin and protein C (PC) zymogen. Factor Va proteolysis was visualized by Western blot analysis using a monoclonal antibody (αHVaHC No. 17) to the factor Va heavy chain (HC), and cofactor activity was followed both in a clotting assay using factor V–deficient plasma and by quantitation of prothrombinase function. APC generation was monitored using the substrate 6-(D-VPR)amino-1-naphthalenebutylsulfonamide (D-VPR-ANSNHC4H9), which permits quantitation of APC at 10 pmol/L. Addition of APC (5 nmol/L) to an adherent HUVEC monolayer (3.5×105 cells per well) resulted in a 75% inactivation of factor Va (20 nmol/L) within 10 minutes, with complete loss of cofactor activity within 2 hours. Measurements of the rate of cleavage at Arg506 and Arg306 in the presence and absence of the HUVEC monolayer indicated that the APC-dependent cleavage of the factor Va HC at Arg506 was accelerated in the presence of HUVECs, while cleavage at Arg306 was dependent on the presence of the HUVEC surface. Factor Va inactivation proceeded with initial cleavage of the factor Va HC at Arg506, generating an Mr 75 000 species. Further proteolysis at Arg306 generated an Mr 30 000 product. When protein C (0.5 μmol/L), α-thrombin (1 nmol/L), and factor Va (20 nmol/L) were added to HUVECs an APC generation rate of 1.56±0.11×10−14 mol/min per cell was observed. With APC generated in situ, cleavage at Arg506 on the HUVEC surface is followed by cleavage at Arg306, generating Mr 75 000 and Mr 30 000 fragments, respectively. In addition, the appearance of two novel products derived from the factor Va HC are observed when thrombin is present on the HUVEC surface: the HC is processed through limited thrombin proteolysis to generate an Mr 97 000 fragment, which is further processed by APC to generate an Mr 43 000 fragment. NH2-terminal sequence analysis of the Mr 97 000 fragment revealed that the thrombin cleavage occurs in the COOH-terminus of the intact factor Va HC since both the intact HC as well as the Mr 97 000 fragment have the same sequence. Our data demonstrate that the inactivation of factor Va on the HUVEC surface, initiated either by APC addition or PC activation, follows a mechanism whereby cleavage is observed first at Arg506 followed by a second cleavage at Arg306. The latter cleavage is dependent on the availability of the HUVEC surface. This mechanism of inactivation of factor Va is similar to that observed on synthetic phospholipid vesicles.
Am Heart Assoc